Detail of "160415-07-6"

Reference

Proconvulsive effect of the GABAB receptor antagonist SCH 50911 in rats undergoing ethanol withdrawal syndrome

Proconvulsive effect of the GABAB receptor antagonist SCH 50911 in rats undergoing ethanol withdrawal syndrome. Carai, Mauro A. M.; Brunetti, Giuliana; Lobina, Carla; Serra, Salvatore; Vacca, Giovanni; Minardi, Giovanna; Colombo, Giancarlo; Gessa, Gian Luigi (Neuroscienze S.c.a r.l., Via Palabanda 9, Cagliari I-09123, Italy). European Journal of Pharmacology, 445(3), 195-199 (English) 2002 Elsevier Science B.V. CODEN: EJPHAZ. ISSN: 0014-2999. DOCUMENT TYPE: Journal CA Section: 4 (Toxicology) Section cross-reference(s): 1 The effect of the GABAB receptor antagonist SCH 50911 on the occurrence of seizures was studied in ethanol-dependent rats undergoing ethanol-withdrawal syndrome. The acute administration of nonconvulsive doses of SCH 50911 (100, 170 and 300 mg/kg, i.p.) markedly facilitated spontaneous seizure occurrence. This finding, together with the reported ability of the GABAB receptor agonist baclofen to suppress seizures assocd. with ethanol withdrawal syndrome, suggests that the GABAB receptor may be part of the neural substrate underlying the hyperexcitability of ethanol-withdrawal syndrome.Except for chemicals metioned above, 64-17-5 and 160415-07-6 are also used. .

Anti-seizure effects of the GABAB antagonist, SCH-50911, in the genetic absence epilepsy rat from Strasbourg (GAERS)

Anti-seizure effects of the GABAB antagonist, SCH-50911, in the genetic absence epilepsy rat from Strasbourg (GAERS). Richards, D. A.; Bowery, N. G. (Medical School, University Birmingham, Birmingham B15 2TT, UK). Pharmacology Reviews and Communications, 8(2-3, 3rd International GABAB Symposium, 1996), 227-230 (English) 1996 Harwood. CODEN: PHRCF6. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Section cross-reference(s): 2 The effect of GABAB antagonist, SCH-50911 (I), administration on spike-and-wave discharges (SWD) in the genetic absence epilepsy rat from Strasbourg (GAERS) model, and its capacity to to induce convulsive seizures at high doses was investigated. Twelve GAERS (wt. 250-300 g) received either (i) 1 mg/kg I i.p (n=4), (ii) 2 mg/kg I i.p (n=4), or (iii) 1 mL/kg vehicle (distd. water) i.p (n=4), and SWD was noted from EEG signal. At a dose of 1 mg/kg I, there was a significant decrease in SWD duration. Increasing the dosage to 2 mg/kg almost eliminated SWD for the duration of the expt. Of the 7 rats who received the much higher dose of 100 mg/kg I, one had repeated tonic-clonic seizure after drug administration. 160415-07-6 which is the cas registry number of one of substances is just one of reagents here. The results confirm, in GAERS, the anti-seizure effect of I. Comparison of EDs against GABAB receptor binding consts. also suggest that I may penetrate the brain more effectively than the phosphinic acid-based GABAB antagonists. .